Giuseppe
Emeritus
Authors' reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children (Euro Surveill., extract, edited)
[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19681">Eurosurveillance - View Article</cite>. 1st paragraph, edited.]
Eurosurveillance, Volume 15, Issue 40, 07 October 2010
Letters
Authors' reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children
H Kelly 1, D Carcione 2, G Dowse 2, P Effler 2
1. Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
2. Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia
Citation style for this article: Kelly H, Carcione D, Dowse G, Effler P. Authors' reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children. Euro Surveill. 2010;15(40)
ii=19681. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19681
Date of submission: 05 October 2010
To the editor:
Dr Lopert from Australia?s regulatory body for therapeutic goods, the Therapeutics Goods Administration (TGA), raises a number of issues about our quantification of the risk-benefit ratio for seasonal trivalent influenza vaccines administered to children aged six months to four years in Australia in 2010 [1]. While we continue to believe the current data support vaccination of healthy children, it is important to conduct robust post-marketing surveillance, support an open scientific discussion of the observations, and ensure a rapid, comprehensive response to any potential adverse events following immunisation (AEFI).
(...)
-
------
[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19681">Eurosurveillance - View Article</cite>. 1st paragraph, edited.]
Eurosurveillance, Volume 15, Issue 40, 07 October 2010
Letters
Authors' reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children
H Kelly 1, D Carcione 2, G Dowse 2, P Effler 2
1. Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
2. Communicable Disease Control Directorate, Department of Health Western Australia, Perth, Australia
Citation style for this article: Kelly H, Carcione D, Dowse G, Effler P. Authors' reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children. Euro Surveill. 2010;15(40)
ii=19681. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19681Date of submission: 05 October 2010
To the editor:
Dr Lopert from Australia?s regulatory body for therapeutic goods, the Therapeutics Goods Administration (TGA), raises a number of issues about our quantification of the risk-benefit ratio for seasonal trivalent influenza vaccines administered to children aged six months to four years in Australia in 2010 [1]. While we continue to believe the current data support vaccination of healthy children, it is important to conduct robust post-marketing surveillance, support an open scientific discussion of the observations, and ensure a rapid, comprehensive response to any potential adverse events following immunisation (AEFI).
(...)
-
------